Aspergillosis - Pipeline Insight, 2024

Aspergillosis - Pipeline Insight, 2024

DelveInsight’s, “Aspergillosis - Pipeline Insight, 2024,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Aspergillosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Aspergillosis Understanding

Aspergillosis: Overview

Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Aspergillus spores present in the environment can be taken inside the body while breathing which leads to aspergillosis. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. Types of Aspergillosis are Allergic bronchopulmonary aspergillosis (ABPA), Allergic Aspergillus sinusitis, Azole-Resistant Aspergillus fumigatus, Aspergilloma, Chronic pulmonary aspergillosis, Invasive aspergillosis, and Cutaneous (skin) aspergillosis. Diagnosis of Aspergillosis is done by examining the patient history and various tests including blood tests to check for antibodies, allergens, and fungus molecules; X-ray; CT scan, and/or sputum stain and culture to examine the bronchial mucus. Treatment options for Aspergillosis include oral corticosteroids, antifungal medications, and surgery.

""Aspergillosis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Aspergillosis pipeline landscape is provided which includes the disease overview and Aspergillosis treatment guidelines. The assessment part of the report embraces, in depth Aspergillosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Aspergillosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Aspergillosis R&D. The therapies under development are focused on novel approaches to treat/improve Aspergillosis.
• In April 2021, Pulmatrix announced it will regain full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, following Johnsons & Johnson's Enterprise Innovation's decision to terminate the Company's license, development and commercialization agreement. Pulmatrix intends to continue the development of PUR1800, with ongoing clinical and toxicology studies to support programs in acute exacerbations in COPD (AECOPD) and other chronic airway diseases.

Aspergillosis Emerging Drugs Chapters

This segment of the Aspergillosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Aspergillosis Emerging Drugs

• PC945: Pulmocide

PC945 is a potent, long-acting antifungal triazole, possesses activity against a broad range of both azole-susceptible and azole-resistant strains of Aspergillus fumigatus. PC945 is being developed as an inhaled treatment for pulmonary aspergillosis. It has been designed to deliver high local lung concentrations, retention in lung tissues that offers a long duration of action and minimal systemic exposure.

• Dupilumab: Regeneron/Sanofi

Dupilumab (Dupixent) is an interleukin-4 (IL-4) receptor alpha antagonist. It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit. Dupilumab is currently being studied in Phase III developmental studies for the treatment of patients with Allergic Bronchopulmonary Aspergillosis.

Further product details are provided in the report……..

Aspergillosis: Therapeutic Assessment

This segment of the report provides insights about the different Aspergillosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Aspergillosis

There are approx. 20+ key companies which are developing the therapies for Aspergillosis. The companies which have their Aspergillosis drug candidates in the most advanced stage, i.e. Phase III include, Regeneron/Sanofi.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Aspergillosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Aspergillosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Aspergillosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Aspergillosis drugs.

Aspergillosis Report Insights

• Aspergillosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Aspergillosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Aspergillosis drugs?
• How many Aspergillosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Aspergillosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Aspergillosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Aspergillosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Regeneron/Sanofi
• Pulmocide
• Astellas Pharma
• Cipla/Pulmatrix
• F2G
• Cellix Bio
• SCYNEXIS
• TFF Pharmaceuticals
• Matinas BioPharma
• Amplyx Pharmaceuticals
• Cidara Therapeutics
• ImmuPharma
• Takis

Key Products

• Dupilumab
• PC945
• Isavuconazole
• Itraconazole inhaled
• Olorofim
• CLX-PUL-597E
• Ibrexafungerp
• TFF VORI
• MAT2203
• APX 2041
• Rezafungin acetate
• BioAMP B
• Trazimab